Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
Yasin HussainEsther DrillChau T DangJennifer E LiuRichard M SteingartAnthony F YuPublished in: Breast cancer research and treatment (2019)
Continuation of trastuzumab after an asymptomatic LVEF decline to < 50% in patients who are expected to benefit from additional anti-HER2 therapy is a promising approach that warrants further investigation.
Keyphrases
- ejection fraction
- aortic stenosis
- left ventricular
- positive breast cancer
- end stage renal disease
- epidermal growth factor receptor
- newly diagnosed
- chronic kidney disease
- acute myocardial infarction
- stem cells
- peritoneal dialysis
- transcatheter aortic valve replacement
- hypertrophic cardiomyopathy
- aortic valve
- bone marrow
- cardiac resynchronization therapy
- patient reported outcomes
- insulin resistance
- mesenchymal stem cells
- cell therapy
- atrial fibrillation